Published in AIDS Weekly, November 8th, 1999
Thus the compound, dubbed SJ-3366 by Samjin Pharmaceutical Co. Ltd., Seoul, Korea, is the first NNRTI to inhibit both HIV-1 and HIV-2.
"Based on its significantly elevated therapeutic index, SJ-3366 represents an exciting new compound for use in HIV infected individuals," suggested R.W. Buckheit of the Southern Research Institute, Frederick, Maryland.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.